Concepedia

Publication | Open Access

Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation

DOIFull Paper Access

150

Citations

30

References

2021

Year

Wayne A. Ray, Cecilia P. Chung, C. Michael Stein, Walter Smalley, Eli E. Zimmerman, William D. Dupont, Adriana M. Hung, James R. Daugherty, Alyson L. Dickson, Katherine T. Murray
JAMA

Abstract

Among Medicare beneficiaries 65 years or older with atrial fibrillation, treatment with rivaroxaban compared with apixaban was associated with a significantly increased risk of major ischemic or hemorrhagic events.

References

YearCitations

Page 1